Recent developments in research
- LCRF | Boehringer Ingelheim Team Science Award on understanding and treating HER2+ lung cancers
- Connecting the Dots: from urgency to impact in KRAS-mutant lung cancer
- AI for Lung Cancer Screening
- Connecting the Dots: the ALK lung cancer breakthrough
- Connecting the Dots: EGFR-mutated lung cancer
- LCRF + AstraZeneca launch SCLC grant
Science Made Simple
- Zongertinib approved as first-line HER2+ lung cancer treatment
- AI for Lung Cancer Screening
- Lung cancer in 2025
- Subcutaneous amivantamab
- Sevabertinib for HER2+ lung cancer
- Zongertinib for HER2+ lung cancer
- Sunvozertinib for EGFR Exon 20+ NSCLC
- NeoADAURA trial shows promising results
- ADC for EGFR+ lung cancer gets accelerated approval